Fremanezumab for the preventive treatment of migraine in Chinese adults: A Phase 3, randomized controlled trial with an open-label extension
Cephalalgia · 2026-08 · 46 (8)
DOI: 10.1177/03331024261462833 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cephalalgia, online erschienen am 19.08.2026. Verfasst von Shengyuan Yu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Chinese PLA General Hospital, First Medical Center, Beijing, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Migraine Disorders. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Teva Pharmaceuticals.
Abstract (Originalsprache)
Aim
Fremanezumab is approved for migraine prevention in Europe, the United States (US), Japan, South Korea, and several other countries; however, there are no data available on fremanezumab as a migraine preventive treatment in a Chinese population. This study evaluated the efficacy and safety of fremanezumab in Chinese adults with migraine.
Methods
This randomized, multicenter, Phase 3 trial consisted of a 4-week screening period, a 12-week double-blind period (DBP), and a 12-week open-label extension (OLE). Chinese adults with episodic and chronic migraine were randomized 1:1:2 to receive fremanezumab monthly (225 mg), fremanezumab quarterly (675 mg), or matched monthly placebo during the DBP. During the OLE, all participants received fremanezumab monthly (225 mg). The primary endpoint was mean change from baseline in monthly migraine days (MMD) during the DBP. Secondary endpoints included mean change from baseline in migraine days during the first 4 weeks of treatment and in monthly number of days with acute headache medication use during the DBP. Similar endpoints were assessed during the OLE. Safety assessments included, but were not limited to, adverse event (AE) reporting.
Results
In total, 365/454 screened participants were randomized to fremanezumab (n = 182 [monthly, n = 91; quarterly, n = 91]) or placebo (n = 183). Significantly greater changes from baseline in MMD were observed with fremanezumab versus placebo during the DBP (−4.6 vs −2.8; p < 0.0001) and in mean migraine days during the first 4 weeks of treatment (−4.5 vs −2.2; p < 0.0001). The mean change from baseline in days of acute headache medication use during the DBP was −3.0 with fremanezumab and −1.1 for placebo ( p < 0.0001). During the OLE, the mean change from baseline in MMD was −6.8 and −7.2 for those assigned to fremanezumab and placebo, respectively, during the DBP. The percentage of participants with any AE was similar between fremanezumab and placebo groups during the DBP (47% vs 43%); serious AEs were infrequent (fremanezumab, 1%; placebo,
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Chinese PLA General Hospital, First Medical Center, Beijing, China.
- Department of Neurology, Hebei General Hospital, Shijiazhuang, China.
- Department of Neurology, Tianjin Union Medical Center, Tianjin, China.
- Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.
- Teva Pharmaceutical Information Consulting (Shanghai) Co., Ltd, Beijing, China.
- Teva Pharmaceutical Industries Ltd, Tel Aviv, Israel.
ORCID-Profile: Shengyuan Yu, Xiaoping Ning
Förderung
- Teva Pharmaceuticals
Zitieren
APA
Yu, S., Su, H., Wang, H., Zhang, M., Barash, S., Chen, G., Yiu, G., Bryson, J., Kessler, Y., Carmeli Schwartz, Y., Roth-Ben Arie, Z., Benedek-Segal, M., & Ning, X. (2026). Fremanezumab for the preventive treatment of migraine in Chinese adults: A Phase 3, randomized controlled trial with an open-label extension. Cephalalgia, 46(8). https://doi.org/10.1177/03331024261462833
Vancouver
Yu S, Su H, Wang H, Zhang M, Barash S, Chen G, et al. Fremanezumab for the preventive treatment of migraine in Chinese adults: A Phase 3, randomized controlled trial with an open-label extension. Cephalalgia. 2026;46(8). doi:10.1177/03331024261462833
BibTeX
@article{Yu2026,
author = {Yu, Shengyuan and Su, Hui and Wang, Hebo and Zhang, Meiyun and Barash, Steve and Chen, Glenn and Yiu, Gloria and Bryson, Juline and Kessler, Yoel and Carmeli Schwartz, Yael and Roth-Ben Arie, Zipi and Benedek-Segal, Michal and Ning, Xiaoping},
title = {Fremanezumab for the preventive treatment of migraine in Chinese adults: A Phase 3, randomized controlled trial with an open-label extension},
journal = {Cephalalgia},
year = {2026},
volume = {46},
number = {8},
doi = {10.1177/03331024261462833}
}
EUVIMED